Financhill
Sell
40

ATNM Quote, Financials, Valuation and Earnings

Last price:
$1.53
Seasonality move :
2.2%
Day range:
$1.42 - $1.54
52-week range:
$1.03 - $10.14
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.77x
Volume:
160.9K
Avg. volume:
343.7K
1-year change:
-85.24%
Market cap:
$45.5M
Revenue:
$81K
EPS (TTM):
-$1.47

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ATNM
Actinium Pharmaceuticals
-- -$0.28 -100% -7.24% $5.00
BMY
Bristol-Myers Squibb
$10.7B $1.50 -7.24% 102.38% $57.19
LLY
Eli Lilly and
$12.7B $3.46 26.74% 68.13% $972.57
MRK
Merck &
$15.3B $2.14 -1.55% -4.04% $102.71
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
TOVX
Theriva Biologics
-- -$1.56 -- -8.25% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ATNM
Actinium Pharmaceuticals
$1.46 $5.00 $45.5M -- $0.00 0% --
BMY
Bristol-Myers Squibb
$44.12 $57.19 $89.8B 16.52x $0.62 5.53% 1.88x
LLY
Eli Lilly and
$715.56 $972.57 $642.4B 58.22x $1.50 0.76% 13.19x
MRK
Merck &
$73.47 $102.71 $184.5B 10.69x $0.81 4.3% 2.92x
NBY
NovaBay Pharmaceuticals
$0.60 $0.85 $3.5M -- $0.00 0% 0.16x
TOVX
Theriva Biologics
$0.57 $7.00 $1.6M -- $0.00 0% 0.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ATNM
Actinium Pharmaceuticals
-- -3.541 -- 9.03x
BMY
Bristol-Myers Squibb
74.09% 0.332 41.04% 1.10x
LLY
Eli Lilly and
70.96% 0.813 5.19% 0.57x
MRK
Merck &
41.89% 0.358 16.34% 0.80x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
TOVX
Theriva Biologics
-- -2.512 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ATNM
Actinium Pharmaceuticals
-- -$16.6M -95.08% -95.08% -12769.14% -$7.6M
BMY
Bristol-Myers Squibb
$8.2B $3.5B 7.93% 32.01% 30.94% $1.7B
LLY
Eli Lilly and
$10.5B $5.4B 24.21% 78.25% 29.07% -$1.6B
MRK
Merck &
$12.1B $5.9B 21.5% 39.02% 40.03% $1.2B
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
TOVX
Theriva Biologics
-- -$4.6M -- -- -- -$4.7M

Actinium Pharmaceuticals vs. Competitors

  • Which has Higher Returns ATNM or BMY?

    Bristol-Myers Squibb has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of 21.93%. Actinium Pharmaceuticals's return on equity of -95.08% beat Bristol-Myers Squibb's return on equity of 32.01%.

    Company Gross Margin Earnings Per Share Invested Capital
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
    BMY
    Bristol-Myers Squibb
    72.92% $1.20 $67.2B
  • What do Analysts Say About ATNM or BMY?

    Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 242.47%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $57.19 which suggests that it could grow by 29.62%. Given that Actinium Pharmaceuticals has higher upside potential than Bristol-Myers Squibb, analysts believe Actinium Pharmaceuticals is more attractive than Bristol-Myers Squibb.

    Company Buy Ratings Hold Ratings Sell Ratings
    ATNM
    Actinium Pharmaceuticals
    2 1 0
    BMY
    Bristol-Myers Squibb
    4 18 1
  • Is ATNM or BMY More Risky?

    Actinium Pharmaceuticals has a beta of -0.236, which suggesting that the stock is 123.637% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.827%.

  • Which is a Better Dividend Stock ATNM or BMY?

    Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 5.53% to investors and pays a quarterly dividend of $0.62 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

  • Which has Better Financial Ratios ATNM or BMY?

    Actinium Pharmaceuticals quarterly revenues are $81K, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.2B. Actinium Pharmaceuticals's net income of -$15.9M is lower than Bristol-Myers Squibb's net income of $2.5B. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while Bristol-Myers Squibb's PE ratio is 16.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 1.88x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
    BMY
    Bristol-Myers Squibb
    1.88x 16.52x $11.2B $2.5B
  • Which has Higher Returns ATNM or LLY?

    Eli Lilly and has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of 21.68%. Actinium Pharmaceuticals's return on equity of -95.08% beat Eli Lilly and's return on equity of 78.25%.

    Company Gross Margin Earnings Per Share Invested Capital
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
    LLY
    Eli Lilly and
    82.53% $3.06 $54.4B
  • What do Analysts Say About ATNM or LLY?

    Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 242.47%. On the other hand Eli Lilly and has an analysts' consensus of $972.57 which suggests that it could grow by 35.92%. Given that Actinium Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Actinium Pharmaceuticals is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    ATNM
    Actinium Pharmaceuticals
    2 1 0
    LLY
    Eli Lilly and
    15 4 1
  • Is ATNM or LLY More Risky?

    Actinium Pharmaceuticals has a beta of -0.236, which suggesting that the stock is 123.637% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

  • Which is a Better Dividend Stock ATNM or LLY?

    Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.76% to investors and pays a quarterly dividend of $1.50 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ATNM or LLY?

    Actinium Pharmaceuticals quarterly revenues are $81K, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Actinium Pharmaceuticals's net income of -$15.9M is lower than Eli Lilly and's net income of $2.8B. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 58.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 13.19x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
    LLY
    Eli Lilly and
    13.19x 58.22x $12.7B $2.8B
  • Which has Higher Returns ATNM or MRK?

    Merck & has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of 32.71%. Actinium Pharmaceuticals's return on equity of -95.08% beat Merck &'s return on equity of 39.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
    MRK
    Merck &
    77.98% $2.01 $83.2B
  • What do Analysts Say About ATNM or MRK?

    Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 242.47%. On the other hand Merck & has an analysts' consensus of $102.71 which suggests that it could grow by 39.8%. Given that Actinium Pharmaceuticals has higher upside potential than Merck &, analysts believe Actinium Pharmaceuticals is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    ATNM
    Actinium Pharmaceuticals
    2 1 0
    MRK
    Merck &
    11 12 0
  • Is ATNM or MRK More Risky?

    Actinium Pharmaceuticals has a beta of -0.236, which suggesting that the stock is 123.637% less volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

  • Which is a Better Dividend Stock ATNM or MRK?

    Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.3% to investors and pays a quarterly dividend of $0.81 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ATNM or MRK?

    Actinium Pharmaceuticals quarterly revenues are $81K, which are smaller than Merck & quarterly revenues of $15.5B. Actinium Pharmaceuticals's net income of -$15.9M is lower than Merck &'s net income of $5.1B. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while Merck &'s PE ratio is 10.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 2.92x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
    MRK
    Merck &
    2.92x 10.69x $15.5B $5.1B
  • Which has Higher Returns ATNM or NBY?

    NovaBay Pharmaceuticals has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of -49.65%. Actinium Pharmaceuticals's return on equity of -95.08% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About ATNM or NBY?

    Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 242.47%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 42.86%. Given that Actinium Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Actinium Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ATNM
    Actinium Pharmaceuticals
    2 1 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is ATNM or NBY More Risky?

    Actinium Pharmaceuticals has a beta of -0.236, which suggesting that the stock is 123.637% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock ATNM or NBY?

    Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ATNM or NBY?

    Actinium Pharmaceuticals quarterly revenues are $81K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Actinium Pharmaceuticals's net income of -$15.9M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M -$1.2M
  • Which has Higher Returns ATNM or TOVX?

    Theriva Biologics has a net margin of -11511.11% compared to Actinium Pharmaceuticals's net margin of --. Actinium Pharmaceuticals's return on equity of -95.08% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
    TOVX
    Theriva Biologics
    -- -$1.60 --
  • What do Analysts Say About ATNM or TOVX?

    Actinium Pharmaceuticals has a consensus price target of $5.00, signalling upside risk potential of 242.47%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1134.13%. Given that Theriva Biologics has higher upside potential than Actinium Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Actinium Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ATNM
    Actinium Pharmaceuticals
    2 1 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is ATNM or TOVX More Risky?

    Actinium Pharmaceuticals has a beta of -0.236, which suggesting that the stock is 123.637% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock ATNM or TOVX?

    Actinium Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ATNM or TOVX?

    Actinium Pharmaceuticals quarterly revenues are $81K, which are larger than Theriva Biologics quarterly revenues of --. Actinium Pharmaceuticals's net income of -$15.9M is lower than Theriva Biologics's net income of -$4.4M. Notably, Actinium Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
    TOVX
    Theriva Biologics
    0.63x -- -- -$4.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Will Bloom Energy Stock Go?
How High Will Bloom Energy Stock Go?

Bloom Energy (NYSE:BE) has seen its shares surge by more…

Is Acuity a Good Stock to Buy Now?
Is Acuity a Good Stock to Buy Now?

Acuity Brands (NYSE:AYI) is an industrial company specializing in lighting.…

What Stocks Are Recession-Proof?
What Stocks Are Recession-Proof?

Fears of a recession prevailed in Q2 2025 when the…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 38x

Buy
74
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
49
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
71
NUTX alert for May 15

Nutex Health [NUTX] is up 9.76% over the past day.

Buy
81
EXEL alert for May 15

Exelixis [EXEL] is up 3.67% over the past day.

Sell
29
GLBE alert for May 15

Global E Online [GLBE] is down 3.44% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock